2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 ☆
Parsons H, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson V, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina T, Carey L, Rimawi M, Miller K, Stearns V, Specht J, Falkson C, Burstein H, Wolff A, Winer E, Tayob N, Krop I, Makrigiorgos G, Golub T, Mayer E, Adalsteinsson V. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 ☆. Annals Of Oncology 2023, 34: 899-906. PMID: 37597579, PMCID: PMC10898256, DOI: 10.1016/j.annonc.2023.08.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerResidual cancer burdenNeoadjuvant chemotherapyCancer burdenBreast cancerWeek 3Additional neoadjuvant chemotherapyPlasma samplesCase-control analysisCtDNA clearanceCtDNA positivityNeoadjuvant paclitaxelDisease recurrenceProspective studyWeek 12RCB 0CtDNA assaysPatientsSufficient tissueChemotherapyTumor fractionTumor DNARCB-3RespondersAdditional studies
2004
Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants
Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, Bauer-Wu S, Knudsen K, Emmons K, Collyar D, Schilsky RL, Winer EP. Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants. Journal Of The National Cancer Institute 2004, 96: 629-632. PMID: 15100341, DOI: 10.1093/jnci/djh096.Peer-Reviewed Original ResearchConceptsTrial resultsMost patientsOncology physiciansClinical trialsClinical trial resultsOncology clinical trialsPatientsEligible membersNurses' practicePatients' difficultiesRespondersNegative emotional effectsTrialsPhysiciansFuture studiesOne-fifthParticipantsStudy resultsCancerCliniciansNursesResults of studiesEmotional effects